LEADER 01095nam--2200361---450- 001 990003244680203316 005 20090514102631.0 035 $a000324468 035 $aUSA01000324468 035 $a(ALEPH)000324468USA01 035 $a000324468 100 $a20090514d1974----km-y0itay50------ba 101 $afre 102 $aSU 105 $a||||||||001yy 200 1 $aEnveloppes$fV. Boltianski 210 $aMoscou$cEditions MIR$d1974 215 $a264 p.$cfig.$d17 cm 225 2 $aInitiation aux mathématiques 327 1 $aDémostration géométriques: A. Fetissov; - Erreurs dans les dèmonstrations gèométriques: I. Doubnov 454 1$12001$aTraduit du russe par O. Smirnov$923882 606 0 $aGeometria 676 $a516 700 1$aBOLTIANSKI,$bV.$012105 801 0$aIT$bsalbc$gISBD 912 $a990003244680203316 951 $a516 BOL$b1856/CBS$c516$d00220977 959 $aBK 969 $aSCI 979 $aRSIAV6$b90$c20090514$lUSA01$h1026 979 $aRSIAV6$b90$c20090514$lUSA01$h1026 996 $aTraduit du russe par O. Smirnov$923882 997 $aUNISA LEADER 03602nam 22006014a 450 001 9910830148103321 005 20230617020259.0 010 $a1-280-27119-1 010 $a9786610271191 010 $a0-470-86119-3 010 $a0-470-86115-0 035 $a(CKB)111090529061268 035 $a(EBL)189682 035 $a(SSID)ssj0000103158 035 $a(PQKBManifestationID)11113643 035 $a(PQKBTitleCode)TC0000103158 035 $a(PQKBWorkID)10061099 035 $a(PQKB)10706289 035 $a(MiAaPQ)EBC189682 035 $a(OCoLC)85820770 035 $a(EXLCZ)99111090529061268 100 $a20040825d2004 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAnaphylaxis$b[electronic resource] 210 $aChichester ;$aHoboken, NJ $cJohn Wiley & Sons$d2004 215 $a1 online resource (308 p.) 225 1 $aNovartis Foundation symposium ;$v257 300 $a"Symposium on Anaphylaxis, held at the Novartis Foundation, 25-27 February 2003; editors, Gregory Bock (organizer) and Jamie Goode."--Contents p. 311 $a0-470-86114-2 320 $aIncludes bibliographical references and indexes. 327 $aANAPHYLAXIS; Contents; Participants; Chair's introduction; History and classification of anaphylaxis; Discussion; Rethinking Th2 antibody responses and allergic sensitization; Discussion; General discussion I; The high affinity receptor for IgE, FceRI; Discussion; Effector cells of anaphylaxis: mast cells and basophils; Discussion; Cytokine enhancement of anaphylaxis; Discussion; General discussion II; Patterns of anaphylaxis: acute and late phase features of allergic reactions; Discussion; Fatal anaphylaxis in the UK, 1992-2001; Discussion; The human heart as a shock organ in anaphylaxis 327 $aDiscussion General discussion III; Food-induced anaphylaxis; Discussion; Anaphylaxis to insect venom; Discussion; Anaphylaxis to anaesthetic drugs; Discussion; General discussion IV; The radiocontrast molecule in anaphylaxis. A surprising antigen; Discussion; General discussion V Fatal course of Vespula venom immunotherapy: pretreatment withdrawal of the b blocker may have been involved; Epinephrine (adrenaline) in the first-aid, out-of-hospital treatment of anaphylaxis; Discussion; New approaches for the treatment of anaphylaxis; Discussion 327 $aPatient's perspective and public policy regarding anaphylaxis Discussion; Final discussion; Index of contributors; Subject index 330 $aAnaphylaxis is an immediate-type allergic reaction involving the whole organism. It is the most life-threatening allergic condition. Although there are few exact epidemiological data regarding prevalence, estimates regarding insect sting anaphylaxis range from 1-3% in the general population, but much higher values have been reported by some authors for food and drug-induced anaphylaxis. Anaphylaxis is the main acute killer of allergic individuals.Although anaphylaxis was discovered at the beginning of the 20th century, there are still many unresolved issues. These include non-IgE-mediated 410 0$aNovartis Foundation symposium ;$v257. 606 $aAnaphylaxis$vCongresses 615 0$aAnaphylaxis 676 $a614.5/993 676 $a616.97 701 $aBock$b Gregory$0322650 701 $aGoode$b Jamie$0283336 712 02$aNovartis Foundation. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830148103321 996 $aAnaphylaxis$93984818 997 $aUNINA